Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome

被引:15
作者
Arguello, Annie [1 ]
Meisner, Rene [1 ]
Thomsen, Elliot R. [1 ]
Nguyen, Hoang N. [1 ]
Ravi, Ritesh [1 ]
Simms, Jeffrey [2 ]
Lo, Iris [2 ]
Speckart, Jessica [2 ]
Holtzman, Julia [2 ]
Gill, Thomas M. [2 ]
Chan, Darren [1 ]
Cheng, Yuhsiang [1 ]
Chiu, Chi-Lu [1 ]
Dugas, Jason C. [1 ]
Fang, Meng [1 ]
Lopez, Isabel A. [1 ]
Solanoy, Hilda [1 ]
Tsogtbaatar, Buyankhishig [1 ]
Zhu, Yuda [1 ]
Bhalla, Akhil [1 ]
Henne, Kirk R. [1 ]
Henry, Anastasia G. [1 ]
Delucchi, Anthony [1 ]
Costanzo, Simona [1 ]
Harris, Jeffrey M. [1 ]
Diaz, Dolores [1 ]
Scearce-Levie, Kimberly [1 ]
Sanchez, Pascal E. [1 ]
机构
[1] Denali Therapeut Inc, San Francisco, CA 94080 USA
[2] Gladstone Inst Neurol Dis, Behav Core, San Francisco, CA USA
关键词
ENZYME REPLACEMENT THERAPY; II PATIENTS; MUCOPOLYSACCHARIDOSES; NEURODEGENERATION; MANIFESTATIONS; IDURSULFASE; DISEASE; SULFATE;
D O I
10.1172/jci.insight.145445
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder caused by deficiency of the iduronate-2-sulfatase (IDS) enzyme, resulting in cellular accumulation of glycosaminoglycans (GAGs) throughout the body. Treatment of MPS II remains a considerable challenge as current enzyme replacement therapies do not adequately control many aspects of the disease, including skeletal and neurological manifestations. We developed an IDS transport vehicle (ETV:IDS) that is engineered to bind to the transferrin receptor; this design facilitates receptor-mediated transcytosis of IDS across the blood-brain barrier and improves its distribution into the brain while maintaining distribution to peripheral tissues. Here we show that chronic systemic administration of ETV:IDS in a mouse model of MPS II reduced levels of peripheral and central nervous system GAGs, microgliosis, and neurofilament light chain, a biomarker of neuronal injury. Additionally, ETV:IDS rescued auricular and skeletal abnormalities when introduced in adult MPS II mice. These effects were accompanied by improvements in several neurobehavioral domains, including motor skills, sensorimotor gating, and learning and memory. Together, these results highlight the therapeutic potential of ETV:IDS for treating peripheral and central abnormalities in MPS II. DNL310, an investigational ETV:IDS molecule, is currently in clinical trials as a potential treatment for patients with MPS II.
引用
收藏
页数:17
相关论文
共 43 条
[1]   Musculoskeletal manifestations of lysosomal storage disorders [J].
Aldenhoven, M. ;
Sakkers, R. J. B. ;
Boelens, J. ;
de Koning, T. J. ;
Wulffraat, N. M. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (11) :1659-1665
[2]   Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice [J].
Baldo, Guilherme ;
Mayer, Fabiana Q. ;
Martinelli, Barbara Z. ;
de Carvalho, Talita G. ;
Meyer, Fabiola S. ;
de Oliveira, Patricia G. ;
Meurer, Luise ;
Tavares, Angela ;
Matte, Ursula ;
Giugliani, Roberto .
MOLECULAR GENETICS AND METABOLISM, 2013, 109 (01) :33-40
[3]   Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients [J].
Bhalla, Akhil ;
Ravi, Ritesh ;
Fang, Meng ;
Arguello, Annie ;
Davis, Sonnet S. ;
Chiu, Chi-Lu ;
Blumenfeld, Jessica R. ;
Nguyen, Hoang N. ;
Earr, Timothy K. ;
Wang, Junhua ;
Astarita, Giuseppe ;
Zhu, Yuda ;
Fiore, Damian ;
Scearce-Levie, Kimberly ;
Diaz, Dolores ;
Cahan, Heather ;
Troyer, Matthew D. ;
Harris, Jeffrey M. ;
Escolar, Maria L. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) :1-20
[4]   Adult-born hippocampal neurons promote cognitive flexibility in mice [J].
Burghardt, Nesha S. ;
Park, Eun Hye ;
Hen, Rene ;
Fenton, Andre A. .
HIPPOCAMPUS, 2012, 22 (09) :1795-1808
[5]   Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery [J].
Cardone, M ;
Polito, VA ;
Pepe, S ;
Mann, L ;
D'Azzo, A ;
Auricchio, A ;
Ballabio, A ;
Cosma, MP .
HUMAN MOLECULAR GENETICS, 2006, 15 (07) :1225-1236
[6]   Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment [J].
D'Avanzo, Francesca ;
Rigon, Laura ;
Zanetti, Alessandra ;
Tomanin, Rosella .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (04)
[7]   Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation [J].
Diaz Jacques, Carlos Eduardo ;
Donida, Bruna ;
Mescka, Caroline P. ;
Rodrigues, Daiane G. B. ;
Marchetti, Desiree P. ;
Bitencourt, Fernanda H. ;
Burin, Maira G. ;
de Souza, Carolina F. M. ;
Giugliani, Roberto ;
Vargas, Carmen Regla .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2016, 1862 (09) :1608-1616
[8]   The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome [J].
Eisengart, J. B. ;
King, K. E. ;
Shapiro, E. G. ;
Whitley, C. B. ;
Muenzer, J. .
MOLECULAR GENETICS AND METABOLISM REPORTS, 2020, 22
[9]   Biomarkers in patients with mucopolysaccharidosis type II and IV [J].
Fujitsuka, Honoka ;
Sawamoto, Kazuki ;
Peracha, Hira ;
Mason, Robert W. ;
Mackenzie, William ;
Kobayashi, Hironori ;
Yamaguchi, Seiji ;
Suzuki, Yasuyuki ;
Orii, Kenji ;
Orii, Tadao ;
Fukao, Toshiyuki ;
Tomatsu, Shunji .
MOLECULAR GENETICS AND METABOLISM REPORTS, 2019, 19
[10]   12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment [J].
Gabrielli, Orazio ;
Clarke, Lorne A. ;
Ficcadenti, Anna ;
Santoro, Lucia ;
Zampini, Lucia ;
Volpi, Nicola ;
Coppa, Giovanni V. .
BMC MEDICAL GENETICS, 2016, 17